Feb. 28 (Bloomberg) -- Tsutomu Une, chairman of Ranbaxy Laboratories Ltd., comments on the outlook for generic Lipitor sales. Une, a senior executive officer at Daiichi Sankyo Co., was appointed chairman of Ranbaxy in May 2009 after the Tokyo-based drugmaker acquired control the previous year. He made the comments on a conference call.
“We’ll maintain the current market share of more than 40 percent in the U.S. going forward. Ranbaxy has a strong relationship with its business partners and that’s what’s helping Ranbaxy gain such market share.”
On the consent decree:
“It’s a five-year project. Ranbaxy signed a contract with Arun Sawhney to be the chief executive officer for the next five years, as of Jan. 1, to command and complete the project.
‘‘The decree is in effect as of Jan. 26. Ranbaxy is hiring outside consultants to improve the manufacturing practices and setting up an independent committee to check manufacturing data before filing future products for marketing approval to the regulators.’’
To contact the reporter on this story: Kanoko Matsuyama in Tokyo at email@example.com
To contact the editor responsible for this story: Lena Lee at firstname.lastname@example.org